090 Direct involvement of Bortezomib in the occurrence of heart failure

详细信息    查看全文

• 作者：Benjamin Honton¹ ; Nicolas Dumonteil¹ ; Caroline Rouvellat¹ ; Murielle Roussel² ; Fabien Despas¹ ; Didier Carrie¹ ; Michel Galinier¹ ; Atul Pathak¹
• 刊名：Archives of Cardiovascular Diseases Supplements
• 出版年：2010
• 出版时间：January 2010
• 年：2010
• 卷：2
• 期：1
• 页码：30
• 全文大小：83 K

文摘

Bortezomib is an antitumor therapy for Multiple Myeloma and Non Hodgkin Lymphoma which incidence is dramatically growing up. This drug inhibits proteasome activity through action on the 26 S proteasome in mammalian cells and leads to apoptosis of tumoral cells. Cardiac toxicity of this drug is not clearly established and its mechanistic poorly understood. Moreover, the few reports in the update literature are unable to prove a direct involvement of bortezomib in the occurrence of Acute or Chronic Heart Failure.

We report the first clinical observation of chronic heart failure which can be directly related to administration of bortezomib. This relationship is strongly suggested by the pharmacological Begaud's score for drug adverse events with a high degree of imputability. This observation is further supported by the report of all other cases of cardiac failure associated with bortezomib, reported in the French pharmacovigilance database (table 1).able class=""dataTable"" frame=""hsides"" border=""0"" cellpadding=""0"" rules=""groups"" cellspacing=""0"">an=""11"">ad>align=""left"">ass=""boldFont"">Patientsalign=""left"">ass=""boldFont"">Age (Year)align=""left"">ass=""boldFont"">Genderalign=""left"">ass=""boldFont"">Diseasealign=""left"">ass=""boldFont"">Cardiac Risk Factoralign=""left"">ass=""boldFont"">Prior Chemotherpy regimensalign=""left"">ass=""boldFont"">N¡ãbortezomib containing cyclesalign=""left"">ass=""boldFont"">Cumulated Dose (mg/m^{ass=""boldFont"">2}ass=""boldFont"">)align=""left"">ass=""boldFont"">Cardiac complicationalign=""left"">ass=""boldFont"">deathalign=""left"">ass=""boldFont"">Imputabilityad>align=""center"">#1align=""center"">79align=""center"">Falign=""center"">MMalign=""center"">HTAalign=""center"">0align=""center"">1align=""center"">2,64align=""center"">Acute Heart Failurealign=""center"">yesalign=""center"">I3align=""center"">#2align=""center"">79align=""center"">Falign=""center"">MMalign=""center"">0align=""center"">1align=""center"">6align=""center"">31,2align=""center"">Acute Heart Failurealign=""center"">Noalign=""center"">I1align=""center"">#3align=""center"">71align=""center"">Falign=""center"">MMalign=""center"">0align=""center"">0align=""center"">6align=""center"">31,2align=""center"">Acute Heart Failurealign=""center"">Noalign=""center"">I1align=""center"">#4align=""center"">54align=""center"">Falign=""center"">MMalign=""center"">0align=""center"">2align=""center"">1align=""center"">4,45align=""center"">Cardiogenic Shockalign=""center"">Yesalign=""center"">I1align=""center"">#5align=""center"">74align=""center"">Malign=""center"">MMalign=""center"">0align=""center"">0align=""center"">1align=""center"">3,9align=""center"">Acute Heart Failurealign=""center"">Yesalign=""center"">I4align=""center"">#6align=""center"">61align=""center"">Falign=""center"">MMalign=""center"">HTAalign=""center"">4align=""center"">10align=""center"">54,3align=""center"">Acute Heart Failurealign=""center"">Noalign=""center"">I1align=""center"">#7align=""center"">69align=""center"">Falign=""center"">MMalign=""center"">0align=""center"">0align=""center"">3align=""center"">15,6align=""center"">Acute Heart Failurealign=""center"">Noalign=""center"">I1align=""center"">#8align=""center"">54align=""center"">Malign=""center"">MMalign=""center"">0align=""center"">5align=""center"">3align=""center"">15,6align=""center"">Acute Heart Failurealign=""center"">Noalign=""center"">I1able>